Rezield Needs Advantage Over Synagis, Advisory Cmte. Tells MedImmune
Executive Summary
If MedImmune wants to move forward with Rezield (motavizumab), its preventive treatment for respiratory syncytial virus disease, it will likely have to demonstrate some advantage over its currently approved product, Synagis (palivizumab)
You may also be interested in...
Can You Still Use Surrogate Markers In A Crowded Drug Class? Sollpura Panel Recommends BMI, Weight Endpoints
The troubles that Alnara Pharmaceuticals has had with its application for Sollpura (liprotamase) for exocrine pancreatic insufficiency signal the challenges that developers of other drugs in crowded classes may face at FDA.
Can You Still Use Surrogate Markers In A Crowded Drug Class? Sollpura Panel Recommends BMI, Weight Endpoints
The troubles that Alnara Pharmaceuticals has had with its application for Sollpura (liprotamase) for exocrine pancreatic insufficiency signal the challenges that developers of other drugs in crowded classes may face at FDA.
Lilly's Solpura Advisory Committee Could Hinge On Manufacturing Issues
Alnara, a Lilly subsidiary, says that its exocrine pancreatic insufficiency treatment is supported by two adequate and well-controlled trials, but FDA says that the product has changed so much that only one of them is relevant - and that one doesn't show strong enough efficacy.